Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals has applied for quotation on the ASX of 83,333,313 new ordinary fully paid shares, with an issue date of 20 April 2026. The securities are being issued as part of previously announced transactions, expanding the company’s quoted share base and potentially broadening its investor participation and capital resources.
The additional quoted securities may enhance liquidity in Botanix shares and support the funding of its ongoing pharmaceutical initiatives. This move underscores the company’s continued use of equity markets to back its growth and development strategy within the competitive biotech and pharmaceuticals landscape.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is a listed biotechnology company focused on developing pharmaceutical products, operating within the broader pharmaceuticals and life sciences sector. The company’s ordinary fully paid shares trade on the ASX under the ticker BOT, providing investors access to its drug development and commercialisation activities.
Average Trading Volume: 15,652,456
Technical Sentiment Signal: Sell
Current Market Cap: A$94.92M
See more insights into BOT stock on TipRanks’ Stock Analysis page.